Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.
Dr. Lowell Hart
Advertisement
Articles by Dr. Lowell Hart
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ASCO 2026 That Patients Should Know
2
Pumitamig Shows 70% Response in Advanced Lung Cancer Regardless of PD-L1 Status
3
Lynch Syndrome: Why Upper Endoscopies and Colonoscopy Prep Save My Life
4
How a Teen Cancer Survivor and Her Best Friend Created an App to Help Patients Between Appointments
5